


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy ID6354

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
Bayer (acoramidis)	All Wales Inherited Metabolic Disease Service
Patient/carer groups	All Wales Therapeutics and Toxicology
Amyloidosis UK	Centre
 Addenbrookes Liver Transplant 	Allied Health Professionals Federation
Association	Association of Renal Industries
Arrythmia Alliance	Board of Community Health Councils in
Atrial Fibrillation Association	Wales
British Liver Trust	British National Formulary
Cardiomyopathy UK	Care Quality Commission
Cardiovascular Care Partnership	Cell and Gene Therapy Catapult
Circulation Foundation	Department of Health, Social Services
Gene People	and Public Safety for Northern Ireland
Genetic Alliance UK	Healthcare Improvement Scotland
HEART UK	Medicines and Healthcare products
LIVErNORTH	Regulatory Agency
Liver4Life	National Association of Primary Care
Pumping Marvellous	National Pharmacy Association
Somerville Foundation	National Services Division Control Services Division
South Asian Health Foundation	Scottish Society of Gastroenterology
Specialised Healthcare Alliance	NHS Confederation Section Medicines Consections
	Scottish Medicines Consortium Malas Navigala sign! Allianas
Healthcare professional groups	Wales Neurological Alliance Walsh Covernment
 Association of British Neurologists Association of Genetic Nurses and 	Welsh Government NUS Welse Joint Commissioning
Association of Genetic Nurses and Counsellors	NHS Wales Joint Commissioning Committee
Association of Renal Technologists	
British Association for the Study of the	Possible comparator companies
Liver	Pfizer (tafamidis)
 British Association of Endocrine and Thyroid Surgeons 	Alnylam Pharmaceuticals (vutrisiran)
British Association of Urological	Relevant research groups
Nurses	Brain Research UK
	Cochrane Hepato-Biliary Group



Consultees Commentators (no right to submit or appeal) British Association of Urological Cochrane Metabolic & Endocrine Surgeons Disorders Group **British Cardiovascular Society** Foundation for Liver Research **British Geriatrics Society** Genomics England British Neuropathological Society MRC Clinical Trials Unit British Nuclear Cardiology Society National Centre for Cardiovascular British Society for Gene and Cell **Preventions and Outcomes** National Hospital for Neurology and Therapy Neurosurgery British Society for Genetic Medicine National Institute for Health Research British Society for Heart Failure British Society of Gastroenterology Associated Public Health groups British Society of Paediatric **Public Health Wales** Gastroenterology, Hepatology and **Nutrition UK Health Security Agency** Haemochromatosis UK Institute of Neurology National Heart and Lung Institute National Metabolic Biochemistry Network National Neuroscience Advisory Group Neuromodulation Society of UK and Ireland **Primary Care and Community Neurology Society** Primary Care Cardiovascular Society Primary Care Society for Gastroenterology Royal College of General Practitioners Royal College of Nursing Royal College of Ophthalmologists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Endocrinology **UK Clinical Pharmacy Association** Vascular Society of Great Britain and Ireland Others National Amyloidosis Centre, UCL Department of Health and Social Care



Consultees	Commentators (no right to submit or appeal)
NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.